http://www.zibb.com/all/theme/cq/CombinatoRx+Incorporated Zibb. The Global business search engine. en-US search@zibb.com (RB Search)Copyright (c) 2007 Reed Business Information. All rights reserved.Fri, 20 Nov 2009 11:29:57 GMTFri, 20 Nov 2009 11:29:57 GMT608831http://www.zibb.com/all/theme/cq/CombinatoRx+Incorporated http://www.zibb.com/images/en/g_zibb_logo_beta.gif http://www.zibb.com/article/5684434/xtremepicks+com+www+Xtremepicks+Com+Xtremepicks+Alerts+November+CRXX+RENT+KIRK+and+CTICXtremepicks.com Alerts include CombinatoRx, Incorporated (NASDAQ: CRXX), Rentrak Corporation (Nasdaq: RENT), Kirkland's, Inc. (Nasdaq: KIRK) and Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) CombinatoRx, Incorporated (NASDAQ: CRXX) trading at $0.911 per share on trading volume of 172,349http://www.zibb.com/article/5684434/xtremepicks+com+www+Xtremepicks+Com+Xtremepicks+Alerts+November+CRXX+RENT+KIRK+and+CTICCombinatoRx IncorporatedFri, 20 Nov 2009 11:29:57 GMThttp://www.foxbusiness.com/story/markets/industries/health-care/combinatorx-shares-fall-neuromed-drug-approved-fda/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+foxbusiness%2Flatest+%28FOXBusiness.com+-+Latest+News%29Shares of CombinatoRx fell when it announced Neuromed, with which it has a merger pending, will have to resubmit for FDA approval of its pain drug Exalgo.http://www.foxbusiness.com/story/markets/industries/health-care/combinatorx-shares-fall-neuromed-drug-approved-fda/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+foxbusiness%2Flatest+%28FOXBusiness.com+-+Latest+News%29CombinatoRx IncorporatedMon, 16 Nov 2009 23:56:23 GMThttp://boston.bizjournals.com/boston/stories/2009/11/02/daily25.html?ana=from_rssDrug developer CombinatoRx Inc. narrowed its loss in the third quarter on aggressive cost cutting that resulted in a 36 percent reduction in its workforce. The Cambridge, Mass.http://boston.bizjournals.com/boston/stories/2009/11/02/daily25.html?ana=from_rssCombinatoRx IncorporatedTue, 03 Nov 2009 18:55:52 GMThttp://www.biospace.com/news_story.aspx?StoryID=159856&full=1CAMBRIDGE, Mass.--(BUSINESS WIRE)--CombinatoRx, Incorporated (NASDAQ: CRXX - News) today announced the results of a 12 month knee osteoarthritis (OA) Phase 2 extension trial for Synavive™ (CRx-102) at the American College of Rheumatology (ACR) 2009 Annual Meeting in Philadelphia.http://www.biospace.com/news_story.aspx?StoryID=159856&full=1CombinatoRx IncorporatedWed, 21 Oct 2009 12:00:00 GMThttp://www.bizjournals.com/boston/stories/2009/08/10/daily43.html?ana=from_rssA subsidiary of Clinical Data Inc. and CombinatoRx Inc. have signed a licensing agreement valued at up to $257 million in milestone and royalty payments. The collaboration deal calls for Newton, Mass.http://www.bizjournals.com/boston/stories/2009/08/10/daily43.html?ana=from_rssCombinatoRx IncorporatedThu, 13 Aug 2009 16:15:16 GMThttp://www.xconomy.com/boston/2009/08/13/252m-potential-in-clda-combinatorx-deal/Cambridge, MA-based drug developer CombinatoRx (NASDAQ:[[ticker:CRXX]]) has licensed a compound from Clinical Data (NASDAQ:[[ticker:CLDA]]), of Newton, MA, tohttp://www.xconomy.com/boston/2009/08/13/252m-potential-in-clda-combinatorx-deal/CombinatoRx IncorporatedThu, 13 Aug 2009 13:54:55 GMThttp://www.genengnews.com/news/bnitem.aspx?name=60392772Clinical Data licensed its preclinical candidate for B-cell cancers to CombinatoRx in a deal worth up to $252 million. CombinatoRx will initially develop this adenosine A2A The $25http://www.genengnews.com/news/bnitem.aspx?name=60392772CombinatoRx IncorporatedThu, 13 Aug 2009 00:00:00 GMThttp://seekingalpha.com/article/155178-combinatorx-inc-q2-2009-earnings-call-transcript?source=feedCombinatoRx, Inc. (CRXX)Q2 2009 Earnings CallAugust 10, 2009 8:30 am ET<ahttp://seekingalpha.com/article/155178-combinatorx-inc-q2-2009-earnings-call-transcript?source=feedCombinatoRx IncorporatedMon, 10 Aug 2009 19:11:21 GMThttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=2967027&HITNO=10&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=biotechnology%20pharmaceutical&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R%3adate&R=2967027&THISHREF=http%3a//c.moreover.com/click/here.pl%3fz2066302019%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBiotechnology and Pharmaceutical Industry Search Find Companies, News, Events, Jobs, Directoryhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=2967027&HITNO=10&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=biotechnology%20pharmaceutical&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R%3adate&R=2967027&THISHREF=http%3a//c.moreover.com/click/here.pl%3fz2066302019%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comCombinatoRx IncorporatedThu, 02 Jul 2009 19:02:06 GMThttp://www.canadianbusiness.com/markets/headline_news/article.jsp?content=b024496427&utm_source=markets&utm_medium=rssResponses[0].Article.Ratings.NumberOfRatings;} {var rating = ResponseBatch.Responses[0].Article.Ratings;} {var avgRating = rating.AverageRating;} {/if} {if numRatings !http://www.canadianbusiness.com/markets/headline_news/article.jsp?content=b024496427&utm_source=markets&utm_medium=rssCombinatoRx IncorporatedThu, 02 Jul 2009 17:46:00 GMThttp://finance.yahoo.com/news/CRXX-Merging-with-zacks-3899281767.html?x=0&.v=1On July 1, 2009, CombinatoRx agreed to merge with Neuromed Pharmaceuticals, Inc., a privately-held biopharmaceutical company based in Canada.As per the terms of the all-stockhttp://finance.yahoo.com/news/CRXX-Merging-with-zacks-3899281767.html?x=0&.v=1CombinatoRx IncorporatedThu, 02 Jul 2009 17:14:50 GMThttp://www.bostonherald.com/business/general/view/20090702cambridges_combinatorx_nabs_neuromed/srvc=business&position=recent_bulletCombinatoRx Inc., a Cambridge biotech firm left reeling last fall after a key drug study fizzled, has pinned its future on a combination with the private Canadian firm Neuromed Pharmaceuticals Inc. The ownership structure of the new company hinges on the pending regulatory approval of Neuromed’s...http://www.bostonherald.com/business/general/view/20090702cambridges_combinatorx_nabs_neuromed/srvc=business&position=recent_bulletCombinatoRx IncorporatedThu, 02 Jul 2009 04:12:30 GMThttp://www.reuters.com/article/marketsNews/idUSBNG23674720090701* To merge with private Neuromed in an all-stock deal * To issue about 36 mln new shares to Neuromed shareholders * CombinatoRx shares up 37 pct July 1 (Reuters) - Biopharmaceutical company CombinatoRx Inchttp://www.reuters.com/article/marketsNews/idUSBNG23674720090701CombinatoRx IncorporatedWed, 01 Jul 2009 12:35:10 GMThttp://regulatoryaffairs.pharmaceutical-business-review.com/news/combinatorx_signs_merger_agreement_with_neuromed_090701Merger to brings togather product assets and financial resources of both organizationshttp://regulatoryaffairs.pharmaceutical-business-review.com/news/combinatorx_signs_merger_agreement_with_neuromed_090701CombinatoRx IncorporatedWed, 01 Jul 2009 00:00:00 GMThttp://feeds.bizjournals.com/~r/vertical_36/~3/412940164/daily1.htmlCombinatoRx Inc. watched its stock plunge more than 78 percent in early trading Monday based on mixed clinical trial results for a new knee osteoarthritis treatment. The Cambridge, Mass.-based company (Nasdaq: CRXX) had ended Friday with a stock price of about $3.http://feeds.bizjournals.com/~r/vertical_36/~3/412940164/daily1.htmlCombinatoRx IncorporatedMon, 06 Oct 2008 16:28:05 GMThttp://feeds.marketwatch.com/~r/marketwatch/realtimeheadlines/~3/382210835/quotes.aspGSI Stock Quote, and financial news from the leading provider and award-winning MarketWatch.com.http://feeds.marketwatch.com/~r/marketwatch/realtimeheadlines/~3/382210835/quotes.aspCombinatoRx IncorporatedWed, 03 Sep 2008 10:13:38 GMThttp://www.newratings.com/en/main/company_headline.m?id=1783581NEW YORK, July 29 (newratings.com) - In a research note published yesterday, analysts at Ladenburg Thalmann maintain their "buy" rating on CombinatoRx (ticker: CRXX), while raising their estimates for the company. The target price has been reduced from $7.5 to $6.25. [<ahttp://www.newratings.com/en/main/company_headline.m?id=1783581CombinatoRx IncorporatedTue, 29 Jul 2008 18:19:57 GMThttp://www.istockanalyst.com/article/viewarticle/articleid/2297911There are several positive factors impacting Amphenol Corporation (APH) including favorable conditions prevailing in the Interconnect Products business. The company's top-line growth is benefiting from improved end-market demand, new product rollouts and market share gains. APH is experiencinghttp://www.istockanalyst.com/article/viewarticle/articleid/2297911CombinatoRx IncorporatedWed, 18 Jun 2008 23:04:05 GMThttp://www.prlog.org/10057501-combinatorx-incorporated-premium-company-profile-bharatbook-com.htmlCombinatoRx Incorporated: Premium Company Profile : bharatbook.com. Bharatbook.com has announced the addition of “CombinatoRx Incorporated: Premium Company Profile” to their offeringhttp://www.prlog.org/10057501-combinatorx-incorporated-premium-company-profile-bharatbook-com.htmlCombinatoRx IncorporatedMon, 17 Mar 2008 06:56:13 GMThttp://www.medicalnewstoday.com/articles/86538.phpCombinatoRx, Incorporated (NASDAQ: CRXX) announced that it has received the Marjorie Guthrie Leadership Award from the Huntington's Disease Society of America (HDSA) during their 40th Anniversaryhttp://www.medicalnewstoday.com/articles/86538.phpCombinatoRx IncorporatedWed, 24 Oct 2007 08:20:36 GMThttp://www.icis.com/Articles/2003/08/08/510389/cmr-technology-watch-combinatorx-and-synergistic-drug.htmlWho would have predicted that combining a drug for pneumonia with a powerful antipsychotic would yield a promising candidate for the treatment ofhttp://www.icis.com/Articles/2003/08/08/510389/cmr-technology-watch-combinatorx-and-synergistic-drug.htmlCombinatoRx IncorporatedFri, 08 Aug 2003 20:13:05 GMThttp://www.cbi-biotech.com/commonwealthbio/news2007.html?y=2007601 Biotech Drive, Richmond, VA 23235 | 800-RELY-CBI (804) 648-3820 | email: info@cbi-biotech.com © 2009 Commonwealth Biotechnologies, Inc. Save some green and consider the environmental impact of printing this page.http://www.cbi-biotech.com/commonwealthbio/news2007.html?y=2007CombinatoRx Incorporatedhttp://topics.nytimes.com/top/news/business/companies/combinatorx-inc/index.htmlGet Home Delivery Log In Register Now Home Page My Times Today's Paper Video Most Popular Times Topics Business All NYT New York Times Business World U.S. N.Y. / Region Business Media & Advertising World Business Small Business Your Money DealBook Markets Research Mutual Funds My Portfolio Alertshttp://topics.nytimes.com/top/news/business/companies/combinatorx-inc/index.htmlCombinatoRx Incorporatedhttp://pharmabioingredients.com/news/2006/01/30/combinatorx_posts_positive_study_resultsDrug developer CombinatoRx Inc. said Monday that its experimental osteoarthritis drug significantly reduced patients' pain in a mid-stage study. The trial looked at the drug, CRx-102, in 83 patients with osteoarthritis of the hand over six weeks.http://pharmabioingredients.com/news/2006/01/30/combinatorx_posts_positive_study_resultsCombinatoRx Incorporatedhttp://www.bloomberg.com/apps/news?pid=conewsstory&refer=conews&tkr=CRXX:US&sid=aKFcsotCgncQCAMBRIDGE, Mass.--(BUSINESS WIRE)--March 12, 2008 CombinatoRx, Incorporated (NASDAQ: CRXX) today announced top line results of its randomized, blinded, placebo-controlled Phase 2 proof-of-concept clinical trial of CRx-191 in plaque psoriasis.http://www.bloomberg.com/apps/news?pid=conewsstory&refer=conews&tkr=CRXX:US&sid=aKFcsotCgncQCombinatoRx Incorporated